The impact of mavacamten dosing on wall thickness regression: an insight from longer term follow-up based on genetic profile.
Said AlsidawiKaitlin M RoehlJuan Maria FarinaReza ArsanjaniJohn R GiudicessiJeffrey B GeskeDarrell B NewmanMichael J AckermanSteve R OmmenPublished in: American heart journal (2024)
We hypothesize that this lower dosing attenuated the long-term benefit of mavacamten in genetically positive patients. We believe that the long-term benefit of mavacamten on positive cardiac remodeling is dose-dependent and not solely related to the magnitude of left ventricular outflow gradient decrease.
Keyphrases
- left ventricular
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- heart failure
- preterm infants
- acute myocardial infarction
- prognostic factors
- genome wide
- hypertrophic cardiomyopathy
- optical coherence tomography
- gene expression
- acute coronary syndrome
- patient reported outcomes
- percutaneous coronary intervention
- cardiac resynchronization therapy
- patient reported